J. F. Wright

发表

Transient transfection methods for clinical adeno-associated viral vector production.

J. F. Wright, J. F. Wright, 2009, Human gene therapy.

Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events.

J. F. Wright, Zhu Zen, Y. Espinoza, 2004, Human gene therapy.

Translational nanomedicine: status assessment and opportunities.

James S Murday, Judith Stein, Richard W Siegel, 2009, Nanomedicine : nanotechnology, biology, and medicine.

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery

J. F. Wright, Shangzhen Zhou, H. Spencer, 2013, Molecular therapy. Methods & clinical development.

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial

Kathleen A. Marshall, G. Ying, E. Stone, 2009, The Lancet.

AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness

Kathleen A. Marshall, M. Ashtari, G. Ying, 2012, Science Translational Medicine.

Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll.

J. F. Wright, J. F. Wright, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

The intersection of vector biology, gene therapy, and hemophilia

L. Valentino, J. Staber, J. F. Wright, 2021, Research and practice in thrombosis and haemostasis.

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Kathleen A. Marshall, R. Hertle, M. Maguire, 2008, The New England journal of medicine.

Manufacturing and characterizing AAV-based vectors for use in clinical studies

J. F. Wright, J. F. Wright, J. F. Wright, 2008, Gene Therapy.

Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial

Jean Bennett, Manzar Ashtari, Kathleen A. Marshall, 2016, The Lancet.

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis

P. Tak, J. F. Wright, F. Mingozzi, 2015, PloS one.

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.

J. F. Wright, J. F. Wright, J. Sommer, 2007, Journal of virological methods.

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis.

P. Tak, J. F. Wright, B. Hauck, 2015, Human gene therapy. Clinical development.

Identification and partial characterization of a low affinity metal-binding site in the light chain of tetanus toxin.

J. F. Wright, M. Colomb, M. Pernollet, 1992, The Journal of biological chemistry.

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial

Philip R. Johnson, D. Montefiori, C. Labranche, 2019, The lancet. HIV.

Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation.

J. F. Wright, J. Sommer, G. Pierce, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Specific adeno‐associated virus serotypes facilitate efficient gene transfer into human and non‐human primate mesenchymal stromal cells

J. Rasko, J. F. Wright, Shangzhen Zhou, 2007, The journal of gene medicine.

Design of experiments as a decision tool for cell therapy manufacturing.

M. Porteus, J. F. Wright, R. Bacchetta, 2022, Cytotherapy.

Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

J. F. Wright, J. Sommer, B. Hauck, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.

Wenman Wu, J. F. Wright, W. Xiao, 2006, Human gene therapy.

Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.

Kathleen A. Marshall, S. Russell, J. Wittes, 2019, Ophthalmology.

Host cellular annexin II is associated with cytomegalovirus particles isolated from cultured human fibroblasts

A. Kurosky, J. F. Wright, E. Pryzdial, 1995, Journal of virology.

Erratum: CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

M. Kay, M. Ozelo, J. F. Wright, 2006 .

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Bernd Hauck, Bruce L Levine, David L Porter, 2013, The New England journal of medicine.

Coagulation initiated on herpesviruses.

J. F. Wright, E. Pryzdial, M. R. Sutherland, 1997, Proceedings of the National Academy of Sciences of the United States of America.

A Limited Number of Transducible Hepatocytes Restricts a Wide-Range Linear Vector Dose Response in Recombinant Adeno-Associated Virus-Mediated Liver Transduction

Theresa A. Storm, M. Kay, J. F. Wright, 2002, Journal of Virology.

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A

J. F. Wright, H. Spencer, C. Doering, 2016, Molecular therapy. Methods & clinical development.

Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.

P. Sieving, B. Jeffrey, C. Cukras, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model

A. Burdick, A. Kolykhalov, J. F. Wright, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

V. Haurigot, H. Stedman, J. F. Wright, 2010, Blood.

Host and vector-dependent effects on the risk of germline transmission of AAV vectors.

J. F. Wright, B. Hauck, K. High, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Nature and timing of some sporulation-specific protein changes in Saccharomyces cerevisiae

J. F. Wright, I. Dawes, N. Ajam, 1981, Molecular and cellular biology.

AAV empty capsids: for better or for worse?

J. F. Wright, J. F. Wright, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs

V. Haurigot, H. Stedman, J. F. Wright, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B

C. Dunbar, R. Donahue, M. Metzger, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.

A. Parker, J. F. Wright, L. Couto, 2003, Blood.

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

J. F. Wright, K. High, V. Arruda, 2007, Blood.

PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9.

J. F. Wright, K. High, L. Couto, 2011, Journal of virological methods.

Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid.

J. F. Wright, E. Pryzdial, J. F. Wright, 1994, Blood.

Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material.

L. Zentilin, M. Giacca, L. Tenenbaum, 2014, Human gene therapy.

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

J. F. Wright, V. Arruda, J. Finn, 2020, Molecular therapy. Methods & clinical development.

Hepatitis C Virus Therapy PF-05095808, a Novel Biological Agent for Characterization of the Activity of In Vitro

Frances Burden, P. Troke, J. F. Wright, 2012 .

In Vitro Characterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy

Frances Burden, K. Brady, P. Troke, 2011, Antimicrobial Agents and Chemotherapy.

AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura.

J. F. Wright, Shangzhen Zhou, X. Zheng, 2013, Blood.

Vector characterization methods for quality control testing of recombinant adeno-associated viruses.

J. F. Wright, O. Zelenaia, J. F. Wright, 2011, Methods in molecular biology.

Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

J. F. Wright, Shangzhen Zhou, K. Bankiewicz, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods.

P. Fagone, A. Nienhuis, J. Gray, 2012, Human gene therapy methods.

Systemic Errors in Quantitative Polymerase Chain Reaction Titration of Self-Complementary Adeno-Associated Viral Vectors and Improved Alternative Methods

P. Fagone, A. Nienhuis, J. Gray, 2011 .

Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.

Chunling Tang, J. F. Wright, J. Sommer, 2003, Current opinion in drug discovery & development.

Annexin II enhances cytomegalovirus binding and fusion to phospholipid membranes.

J. F. Wright, E. Pryzdial, D. Waisman, 1999, Biochemistry.

Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of nonhuman primate

J. F. Wright, K. Bankiewicz, J. Bringas, 2014, Molecular therapy. Methods & clinical development.

C1 binding by mouse IgM. The effect of abnormal glycosylation at position 402 resulting from a serine to asparagine exchange at residue 406 of the mu-chain.

J. F. Wright, M. Shulman, D. Isenman, 1990, The Journal of biological chemistry.

Manufacturing and regulatory strategies for clinical AAV2-hRPE65.

J. F. Wright, K. High, J. Wellman, 2010, Current gene therapy.

Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration

Jean Bennett, Gui-Shuang Ying, Francesco Testa, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.

H. Kazazian, R. Sarkar, A. Parker, 2003, Blood.

Assessing the potential for AAV vector genotoxicity in a murine model.

Hojun Li, Frederic D Bushman, Nirav Malani, 2011, Blood.

Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression

L. Sullivan, X. Anguela, M. Carr, 2016 .

High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency

J Montane, E. Ayuso, V. Haurigot, 2010, Gene Therapy.

Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?

J. F. Wright, J. F. Wright, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.

Terence R Flotte, Hiroaki Mizukami, Mauro Giacca, 2010, Human gene therapy.

Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model.

J. F. Wright, K. High, V. Arruda, 2011, Human gene therapy.

Progress and challenges in viral vector manufacturing.

Johannes C. M. van der Loo, J. F. Wright, J. F. Wright, 2016, Human molecular genetics.

A comparison of cAMP phosphodiesterases in normal, malignant, and somatic cell hybrids

J. F. Wright, S. Ayad, J. F. Wright, 1977, Biochemical Genetics.

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Kathleen A. Marshall, V. Mahajan, S. Russell, 2017, The Lancet.

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

W. Jagust, P. Starr, C. Christine, 2009, Neurology.

J. F. Wright, J. F. Wright, 2014, Biomedicines.

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

Richard L. Frock, R. Bak, Christopher A. Vakulskas, 2021, Science Translational Medicine.

Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes

J. F. Wright, Bradley A. Hamilton, J. F. Wright, 2021, Frontiers in Immunology.

Erratum: CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

M. Kay, M. Ozelo, J. F. Wright, 2006 .

Quality Control Testing, Characterization and Critical Quality Attributes of Adeno‐Associated Virus Vectors Used for Human Gene Therapy

J Fraser Wright, J. F. Wright, J. F. Wright, 2020, Biotechnology journal.

New adeno-associated virus strategies to support momentum in the clinic.

J. F. Wright, J. F. Wright, 2011, Human gene therapy.

ERRATUM: People to watch

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

Quantification of adeno-associated virus particles and empty capsids by optical density measurement.

Alan McClelland, J. F. Wright, J. Sommer, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Adeno-associated viral vector manufacturing: keeping pace with accelerating clinical development.

J. F. Wright, J. F. Wright, 2011, Human gene therapy.

Scaling-up production of recombinant AAV vectors for clinical applications.

J. F. Wright, G. Qu, A. McClelland, 2000, Current opinion in drug discovery & development.

Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.

Paolo Melillo, Jean Bennett, Francesco Testa, 2013, Ophthalmology.

An endothelial cell-surface form of annexin II binds human cytomegalovirus.

A. Kurosky, J. F. Wright, S. Wasi, 1994, Biochemical and biophysical research communications.

A mitochondrial intergenic mutation affecting processing of specific yeast mitochondrial transcripts.

J. F. Wright, P. Smooker, A. Linnane, 1988, Nucleic acids research.

C1 binding by murine IgM. The effect of a Pro-to-Ser exchange at residue 436 of the mu-chain.

J. F. Wright, M. Shulman, D. Isenman, 1988, The Journal of biological chemistry.